Silence Therapeutics (SLN) Rating Reiterated by Peel Hunt

Peel Hunt restated their buy rating on shares of Silence Therapeutics (LON:SLN) in a research report report published on Thursday morning.

SLN opened at GBX 84.20 ($1.10) on Thursday. Silence Therapeutics has a 1-year low of GBX 71.88 ($0.94) and a 1-year high of GBX 254.75 ($3.33).

Silence Therapeutics (LON:SLN) last released its earnings results on Tuesday, September 11th. The company reported GBX (12.40) (($0.16)) earnings per share for the quarter.

About Silence Therapeutics

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

Featured Story: Why is insider trading harmful?

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply